Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Airbus Joins Air India A320 Altitude Drop Probe 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
PARSIPPANY, N.J., Feb. 16, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
